don't wait until they run out of cash until they dilute.
Agree. But I said "The current cash in hand (w/o add. milestone from Eddingpharm and w/o new ex-US deal) is more than enough till interim readout" At least 3 possibilities exist to raise cash (other than dilution): - script# - new ex-US deal - next milestone from Eddingpharm
The timing of the interim is "fix": the mix of patients between interim and final won't be changed (both are after full enrollment) -> composite event rate will be "flat", event# will be affected by efficacy event# only. If we assume that the Company prediction (interim: 2016 and final @ the EO2017) is valid, the interim event will be in Q1 (my prediction: 2nd half of Feb). We could calculate the eff% @ different placebo rate and we could guess the possible placebo rate, but none of them affect the timing.
News 
Market Data 
Discover 
